非小细胞肺癌围手术期免疫治疗的最新进展  

Perioperative Immunotherapy for Non-small Cell Lung Cancer:a Review of Neoadjuvant and Adjuvant Immunotherapy

作　　者：洪文元 廖绪强[1,2] 蔡仁中[1,2] 李高 HONG Wen-yuan;LIAO Xu-qiang;CAI Ren-zhong;LI Gao(Department of Thoracic Surgery,Hainan General Hospital;Department of Thoracic Surgery,Hainan Affiliated Hospital of Hainan Medical University,Haikou 570311,China)

机构地区：[1]海南省人民医院胸外科 [2]海南医学院附属海南医院胸外科,海口570311

出　　处：《南昌大学学报（医学版）》2024年第2期88-94,共7页Journal of Nanchang University：Medical Sciences

基　　金：海南省自然科学基金(821MS0822;823MS140)。

摘　　要：非小细胞肺癌(NSCLC)作为肺癌常见的亚型,其病死率居高不下。手术是早中期NSCLC主要治疗手段,但Ⅱb—Ⅲ期患者存在较高复发风险,亟待探索有效的围手术期治疗方案以改善患者生存预后。免疫检查点抑制剂(ICIs)的出现使得免疫治疗逐渐成为多种癌症围手术期治疗的研究热点,近几年来涌现出许多对围手术期NSCLC患者进行免疫治疗的临床试验。免疫治疗临床应用的不断推进也带来许多待解决的问题,需要学界深入讨论。文章就NSCLC围手术期应用新辅助、辅助免疫治疗及免疫治疗新方式的相关临床研究及进展进行综述。As a common subtype of lung cancer,non-small cell lung cancer(NSCLC)causes a high mortality rate.Surgery is the main treatment for early to mid-stage NSCLC,but stageⅡB—Ⅲpatients are at high risk of recurrence,and there is an urgent need to explore effective perioperative therapeutic options to improve the survival prognosis of patients.The emergence of immune checkpoint inhibitors(ICIs)has gradually made immunotherapy a research focus for the perioperative treatment of many types of cancers,and many clinical trials of immunotherapy for perioperative NSCLC patients have emerged in recent years.The clinical application of immunotherapy has also brought about many pending issues that require in-depth discussion.This article reviews the clinical research and progress related to the application of neoadjuvant,adjuvant immunotherapy and new modalities of immunotherapy in the perioperative period of NSCLC.

关 键 词：非小细胞肺癌 围手术期 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]